Serum Bile Acids Are Associated with Pathological Progression of Hepatitis B-Induced Cirrhosis

Chen

J Cellular Molecular Medi

et al. 2020

Chronic hepatitis B (CHB) is a global epidemic disease that may progress to fibrosis, cirrhosis and hepatocellular carcinoma. The role of the liver‐bile acid‐microbiota axis in CHB remains unclear. The aims of this study are to elucidate the alteration of the gut microbiota and its functions in bile acid homeostasis in CHB patients with different degrees of fibrosis. In the present study, we evaluated serum and faecal bile acid profiles in healthy controls and CHB patients with biopsy‐proven diagnosis: patients had stage 0‐1 fibrosis were classified as mild CHB and patients had stage 2‐4 fibrosis were classified as moderate/advanced CHB. The levels of serum total bile acids (BAs) and primary BAs were increased in CHB patients with moderate/advanced fibrosis, whereas faecal total and secondary BAs levels were significantly lower. Analyses of gut microbiota exhibited a trend of decreased abundance in bacteria genera responsible for BA metabolism in CHB patients with moderate/advanced fibrosis. CHB is associated with altered bile acid pool which is linked with the dysregulated gut microbiota. The higher level of FGF‐19 may act in a negative feedback loop for maintaining the bile acid homeostasis.

Section: Discussionsupporting

confidence: 47%

“…According to Genta et al, cirrhotic patients have been shown to have a higher serum primary BAs and the proportions of secondary BAs in bile were lower in advanced cirrhosis . A study performed by Wang et al showed that serum BAs are related with CHB‐induced cirrhosis …”

Section: Introductionmentioning

confidence: 99%

Modulation of bile acid profile by gut microbiota in chronic hepatitis B

Chen

J Cellular Molecular Medi

et al. 2020

“…These studies indicate that the dysbiosis or elevated BA levels may produce substantial hepatic toxicities including a variety of cellular disorders, leading to sustained liver injury. Most importantly, our study on BAs showed that TCA, TCDCA, GCA and GCDCA were the most abundant BAs in blood and significantly increased in patients with cirrhosis and HCC …”

mentioning

confidence: 75%

“…The BA levels in plasma, liver, and feces were quantitatively measured by ultra‐performance liquid chromatography triple quadrupole mass spectrometry (UPLC‐TQMS) according to our previously reported protocol . All separations were performed with an ACQUITY BEH C18 column (1.7 µm, 100 mm × 2.1 mm internal dimensions) (Waters, Milford, MA) (Supporting Information Table 1).…”

Section: Measurement Of Serum Alt and Astmentioning

confidence: 99%

Dysregulated hepatic bile acids collaboratively promote liver carcinogenesis

Xie

Huang

et al. 2016

Intl Journal of Cancer

Self Cite

194

164

Dysregulated bile acids (BAs) are closely associated with liver diseases and attributed to altered gut microbiota. Here, we show that the intrahepatic retention of hydrophobic BAs including deoxycholate (DCA), taurocholate (TCA), taurochenodeoxycholate (TCDCA), and taurolithocholate (TLCA) were substantially increased in a streptozotocin and high fat diet (HFD) induced nonalcoholic steatohepatitis-hepatocellular carcinoma (NASH-HCC) mouse model. Additionally chronic HFD-fed mice spontaneously developed liver tumors with significantly increased hepatic BA levels. Enhancing intestinal excretion of hydrophobic BAs in the NASH-HCC model mice by a 2% cholestyramine feeding significantly prevented HCC development. The gut microbiota alterations were closely correlated with altered BA levels in liver and feces. HFD-induced inflammation inhibited key BA transporters, resulting in sustained increases in intrahepatic BA concentrations. Our study also showed a significantly increased cell proliferation in BA treated normal human hepatic cell lines and a down-regulated expression of tumor suppressor gene CEBPα in TCDCA treated HepG2 cell line, suggesting that several hydrophobic BAs may collaboratively promote liver carcinogenesis.

“…With the injury to liver cells, the creatinine clearance rate of bile acid declines, resulting in an increase in serum bile acid. Thus, bile acid is considered to be a biomarker of hepatic injury [37]. Taurocholic acid is a product of the combination of taurine in liver and bile acid.…”

Section: Discussionmentioning

confidence: 99%

The value of grip test, lysophosphatidlycholines, glycerophosphocholine, ornithine, glucuronic acid decrement in assessment of nutritional and metabolic characteristics in hepatitis B cirrhosis

Yin

Zhang

et al. 2017

PLoS ONE

The liver is essential for the regulation of energy, protein and amino acids, as well as in other aspects of metabolism. To identify efficient indexes for evaluation of nutritional status and metabolic characteristics during different Child-Pugh stages of hepatitis B cirrhosis, 83 patients and 35 healthy individuals were enrolled in our study. We found that grip strength, triceps skinfold thickness (TSF), body fat and skeletal muscle of the patients were reduced compared to the control group (P<0.05). Ultra-high-performance liquid chromatography data combined with mass spectrometry (UPLC-MS) showed that levels of a variety of metabolites, including lysophosphatidylcholines (LysoPCs), glycerophosphocholine, ornithine and glucuronic acid were reduced in the serum of patients with hepatitis B cirrhosis (P<0.001). However, glycerophosphoserine and taurocholic acid levels were higher than in the control group (P<0.001). Moreover, grip strength was correlated with the Child-Pugh score (P<0.05). Serum albumin, total cholesterol, LDL, LysoPCs, glycerophosphocholine, ornithine, glucuronic acid, glycerophosphoserine and taurocholic acid were correlated with the Child-Pugh score (P<0.01). These findings suggested that grip strength and the above small molecular substances might be considered as sensitive and important indexes for evaluating nutritional status and metabolic characteristics of patients with hepatitis B cirrhosis, which may help assess prognosis and adjust nutritional treatment.